[
  {
    "question": "question regard Post polio",
    "option_a": "",
    "option_b": ") is correct. Incorrect alternatives might include ongoing poliovirus infection (which is not a mechanism in PPS), upper motor neuron lesions (since PPS involves lower motor neurons), peripheral neuropathy (due to the sparing of sensory nerves), and myopathy (as muscle changes are secondary to denervation).",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Post\u2010polio syndrome (PPS) is a condition seen in long\u2010term survivors of poliomyelitis. Patients often present decades after the initial infection with new or progressive muscle weakness, fatigue, and pain. The core issue involves long\u2010term changes in motor neurons originally injured by the poliovirus. The underlying mechanism is believed to be a gradual degeneration of the anterior horn cells that survived the initial poliovirus infection. These neurons, which had compensated by sprouting collateral branches to reinnervate muscle fibers, eventually become overburdened and degenerate. Importantly, there is no evidence of ongoing viral replication; it is rather a chronic neurodegenerative process. Clinically, patients with PPS develop new muscle weakness (often affecting muscles that were previously weakened), muscle fatigue, and joint pain. Electromyography (EMG) typically demonstrates chronic denervation and reinnervation patterns, consistent with anterior horn cell dysfunction, while sensory functions remain intact. Diagnosis is mainly clinical, supported by a documented history of poliomyelitis and characteristic EMG findings. Differential diagnoses include other motor neuron disorders (e.g., ALS), myopathies, and deconditioning. The absence of sensory involvement and the presence of a long latency since the acute infection help distinguish PPS. There is no curative treatment for PPS. First-line management includes tailored physical therapy focusing on energy conservation and endurance training. Pain management (with medications that are safe in pregnancy and lactation, when needed) and the use of assistive devices are also important. Pharmacologic interventions are limited, but multidisciplinary supportive care is the mainstay. In pregnant or lactating patients, non-pharmacological therapies are preferred and medications, if needed, should be used following current safety guidelines. In the context of typical answer choices, the option referring to an 'anterior horn cell degeneration' mechanism (here marked as option B) is correct. Incorrect alternatives might include ongoing poliovirus infection (which is not a mechanism in PPS), upper motor neuron lesions (since PPS involves lower motor neurons), peripheral neuropathy (due to the sparing of sensory nerves), and myopathy (as muscle changes are secondary to denervation). 1. PPS typically manifests decades after the initial poliovirus infection. 2. EMG findings of chronic denervation with intact sensory responses are characteristic. 3. Management is supportive; exercise should be balanced with energy conservation. Recent reviews emphasize the role of neurorehabilitation and energy\u2010conservation techniques in improving quality of life in PPS. There is a consensus that no active viral process is ongoing, thus emphasizing supportive rather than disease\u2010modifying treatments.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Long scenario of descending weakness start from face to repiratory then whole body (decending). NCS incremental response. What type of disease?",
    "option_a": "post synaptic disease",
    "option_b": "Presynaptic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Neuromuscular junction disorders can be broadly classified by the site of dysfunction within the synapse. Myasthenia gravis affects the postsynaptic membrane, whereas Lambert-Eaton myasthenic syndrome (LEMS) is a presynaptic disorder. The electrophysiologic response to repetitive nerve stimulation is key in distinguishing these conditions. LEMS results from autoantibodies directed against the presynaptic P/Q-type voltage-gated calcium channels. This reduces calcium influx on nerve stimulation and leads to impaired release of acetylcholine. With repetitive stimulation, residual calcium accumulates in the presynaptic terminal, causing an incremental increase in the compound muscle action potential amplitude. Although the classic presentation of LEMS is proximal muscle weakness (often more pronounced in the lower extremities) with autonomic dysfunction, the scenario described (involving descending weakness starting from the face and respiratory muscles before involving the whole body) along with an incremental response on nerve conduction study supports a presynaptic defect. The incremental response is a hallmark of LEMS, distinguishing it from postsynaptic disorders, which show a decremental pattern. Diagnosis relies on electrodiagnostic studies (repetitive nerve stimulation demonstrating an incremental response) and the detection of anti-VGCC antibodies. Differential diagnoses include myasthenia gravis (postsynaptic, showing a decremental response), botulism (which has a presynaptic blockade but a more acute presentation and marked autonomic dysfunction), and other neuromuscular junction disorders. First-line treatment for LEMS is symptomatic management with 3,4-diaminopyridine (3,4-DAP) to enhance acetylcholine release. Immunomodulatory therapies such as corticosteroids, IVIG, or plasma exchange may be considered, particularly in paraneoplastic cases. In patients who are pregnant or lactating, careful consideration is required when using immunosuppressive agents; non-pharmacologic therapies and close monitoring are advisable. Option A (postsynaptic disorder) is incorrect because a postsynaptic defect (as seen in myasthenia gravis) would produce a decremental response on repetitive nerve stimulation. Option B (presynaptic disorder) is correct given the incremental response seen in LEMS. Other options, not provided here, do not align with the electrophysiological findings described. 1. An incremental response on repetitive nerve stimulation is highly suggestive of a presynaptic disorder like LEMS. 2. LEMS can be a paraneoplastic phenomenon, so evaluation for an underlying malignancy is important. 3. Ocular involvement is less prominent in LEMS compared to myasthenia gravis. Recent guidelines emphasize the role of 3,4-DAP in LEMS management and recommend evaluation for paraneoplastic causes. Advances in antibody assays have improved diagnostic accuracy, and emerging data guide the safe use of immunotherapy even in special populations such as pregnant patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What medication can cause Positive romberg & scenario suggestive of sensory neuronopathy",
    "option_a": ", which implicates pyridoxine (vitamin B6) as the cause, is correct. Other medications not known to cause dorsal column toxicity would be less likely to produce the combination of sensory neuronopathy and a positive Romberg sign. Although the question does not list the other options explicitly, the emphasis on pyridoxine in the option analysis supports its selection.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Sensory neuronopathy involves injury or dysfunction of the dorsal root ganglia, leading to profound deficits in proprioception and vibration sense. One of the hallmark clinical signs is a positive Romberg test, indicating loss of proprioceptive input leading to balance problems. Pyridoxine (vitamin B6), when ingested in excess, is neurotoxic and can lead to a sensory neuropathy that predominantly affects the large myelinated fibers responsible for proprioception. Both high doses (toxicity) and severe deficiency (especially when impaired by medications like isoniazid) can lead to dorsal column dysfunction, although toxicity is more commonly implicated in iatrogenic cases. Patients experiencing pyridoxine-induced sensory neuronopathy may present with sensory ataxia, numbness, and a positive Romberg sign. They often have difficulties with balance and coordination, particularly in low-light conditions when proprioceptive input is critical. A thorough medication and supplement history is vital. Electrophysiologic studies may show reduced sensory nerve action potentials. Differential diagnoses include other causes of sensory ataxia such as dorsal column disorders due to vitamin B12 deficiency, tabes dorsalis, or other toxin-induced neuropathies. Laboratory testing of pyridoxine levels can help confirm the etiology. The primary management is discontinuation or adjustment of the offending agent (excessive vitamin B6 supplementation). Neurological recovery may be partial and supportive care including physical therapy is important. In pregnant or lactating women, vitamin supplementation should be carefully managed, avoiding doses that exceed the recommended daily allowance, to prevent neurotoxicity while maintaining maternal and fetal health. Option A, which implicates pyridoxine (vitamin B6) as the cause, is correct. Other medications not known to cause dorsal column toxicity would be less likely to produce the combination of sensory neuronopathy and a positive Romberg sign. Although the question does not list the other options explicitly, the emphasis on pyridoxine in the option analysis supports its selection. 1. High doses of vitamin B6 can be neurotoxic and lead to a sensory neuronopathy with a positive Romberg sign. 2. Always review the patient\u2019s supplement and medication history when assessing unexplained sensory deficits. 3. Management is primarily supportive, with the key intervention being removal of the offending agent. Recent studies have re-emphasized the neurotoxic potential of pyridoxine at doses above the safe upper limit. Updated guidelines advise clinicians to monitor vitamin B6 intake closely, especially in patients self-medicating with over-the-counter supplements.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario suggestive of subacute combined degeneration in patient with gastric sleeve 6 months ago, B12, and MMA normal, what to do next",
    "option_a": "nalysis identifies two critical components: checking the copper level is essential because copper deficiency is the leading mimic of SCD in this clinical context, and assessing folate levels contributes to a complete nutritional profile. Since neither check alone is sufficient, the best next step is a combined approach (represented here by option C), making the marked answer correct.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuromuscular",
    "explanation": "Subacute combined degeneration (SCD) typically arises due to vitamin B12 deficiency leading to demyelination in the dorsal columns and lateral corticospinal tracts. However, similar clinical findings can be seen in other nutritional deficiencies, particularly copper deficiency, which is a known mimic of SCD. Copper is essential for the proper function of several enzymes involved in myelin formation. After bariatric procedures like a gastric sleeve, patients are at risk for various micronutrient deficiencies due to malabsorption. With normal B12 and methylmalonic acid (MMA) levels, copper deficiency becomes a likely culprit and can result in a myelopathy that is clinically and radiologically indistinguishable from classical SCD. Patients with copper deficiency myelopathy typically present with sensory ataxia, spasticity, and sometimes peripheral neuropathy. The history of bariatric surgery raises the index of suspicion for nutritional deficits. While folate deficiency may also be part of the nutritional spectrum post-surgery, it rarely causes a myelopathy of this nature on its own. In such clinical scenarios, a broad nutritional evaluation is recommended. Key investigations include serum copper and ceruloplasmin levels along with folate studies. Differential diagnoses include vitamin E deficiency, neuromyelitis optica, and other metabolic myelopathies; however, the post-gastric sleeve context and normal B12/MMA levels strongly point toward copper deficiency. The first-line approach is to correct the copper deficiency with oral or intravenous copper supplementation, depending on severity. A comprehensive nutritional assessment should include folate evaluation too, although copper deficiency is the primary concern in this context. In pregnant or lactating women, supplementation should be managed carefully to meet maternal and fetal requirements without excess. The option analysis identifies two critical components: checking the copper level is essential because copper deficiency is the leading mimic of SCD in this clinical context, and assessing folate levels contributes to a complete nutritional profile. Since neither check alone is sufficient, the best next step is a combined approach (represented here by option C), making the marked answer correct. 1. Copper deficiency should be suspected in patients with a history of bariatric surgery presenting with SCD-like features, even when B12 levels are normal. 2. A combined nutritional workup is essential to avoid missing coexisting deficiencies. 3. Early recognition of copper deficiency is crucial for preventing irreversible neurological damage. Recent guidelines recommend a broad nutritional screening in patients with neurological symptoms following bariatric surgery. Emerging studies reaffirm the role of copper deficiency in mimicking B12 deficiency myelopathy and advocate for early supplementation to improve outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has stiffness, neuromyotonia on EMG, recurrent LOC, but currently LOC okay, he has positive K ab what is the dx",
    "option_a": "(Isaac syndrome) is correct because it matches the clinical picture: muscle stiffness, neuromyotonia on EMG, and positive potassium channel antibodies. Option B (Morvan syndrome) is incorrect because it is usually accompanied by prominent CNS symptoms (insomnia, hallucinations, encephalopathy) which are not reported here. The marked answer (option C) does not correspond with these hallmark features and is therefore incorrect.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "Isaac syndrome (acquired neuromyotonia) is a rare peripheral nerve hyperexcitability disorder. Patients typically present with muscle stiffness, cramps, fasciculations, and continuous muscle activity that can be demonstrated on electromyography (EMG) as neuromyotonic discharges. The presence of antibodies against voltage\u2010gated potassium channels (VGKC) supports an autoimmune etiology. The underlying mechanism in Isaac syndrome involves autoimmune antibodies (often against VGKC) targeting nerve terminal potassium channels, which leads to prolonged depolarization and hyperexcitability of the peripheral nerves. This results in spontaneous muscle fiber activity, manifesting as stiffness and myokymia. Although recurrent loss of consciousness (LOC) is less common, some cases report transient central symptoms possibly due to dysregulated peripheral input affecting central networks. Clinically, the patient\u2019s symptoms of persistent stiffness and the EMG findings of neuromyotonia are characteristic. The presence of potassium channel antibodies further solidifies the diagnosis. It is important to differentiate this condition from Morvan syndrome, which in addition to similar peripheral findings, includes prominent central nervous system involvement like severe insomnia, hallucinations, and autonomic instability \u2013 features not described in this case. Diagnosis is based on the clinical presentation, characteristic EMG findings (neuromyotonic discharges), and serological testing for VGKC antibodies. Differential diagnoses include Morvan syndrome (distinguished by CNS involvement), stiff-person syndrome (which typically presents with continuous muscle rigidity but lacks neuromyotonia), and other causes of muscle hyperexcitability. Detailed history and correlation with antibody testing help refine the diagnosis. First-line treatment typically involves symptomatic relief with anticonvulsants and sodium channel blockers (e.g., phenytoin, carbamazepine) to reduce nerve hyperexcitability. Immunomodulatory therapies (such as intravenous immunoglobulin or plasmapheresis) may be considered in severe or resistant cases. In pregnant or lactating women, medication selection should balance maternal benefit with fetal risk; for example, careful use of carbamazepine (monitoring for fetal effects) and consultation with obstetric guidelines is advised. Option A (Isaac syndrome) is correct because it matches the clinical picture: muscle stiffness, neuromyotonia on EMG, and positive potassium channel antibodies. Option B (Morvan syndrome) is incorrect because it is usually accompanied by prominent CNS symptoms (insomnia, hallucinations, encephalopathy) which are not reported here. The marked answer (option C) does not correspond with these hallmark features and is therefore incorrect. 1. Neuromyotonia on EMG and VGKC antibody positivity are key diagnostic clues for Isaac syndrome. 2. Differentiation from Morvan syndrome is primarily based on the absence of significant CNS symptoms. 3. Management is largely symptomatic with the potential addition of immunotherapies in refractory cases. Recent studies continue to support the role of autoimmune mechanisms in Isaac syndrome. Current guidelines and reviews highlight the importance of electrophysiological studies and antibody testing in its diagnosis; immunomodulatory therapies have shown promise in selected cases, though symptomatic management remains the cornerstone. Ongoing research is exploring more targeted immunotherapies, and clinicians are advised to follow the latest consensus recommendations when managing special populations such as pregnant women.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Lady with hx of lung cancer, treated with radiation therapy 6 months ago came with 2 months of shoulder discomfort, weak shoulder abduction and elbow flexion, NCS/EMG showed fibs in hands and forearm muscles what to do next",
    "option_a": "(immediate surgical exploration or biopsy) is incorrect because the condition is non",
    "option_b": "(supportive management without further invasive intervention) is correct\u2014as it implies no aggressive treatment is needed beyond symptom management. Options involving chemotherapy or steroids are inappropriate because they do not address the fibrotic, non",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Radiation-induced plexopathy is a recognized complication following radiation therapy, particularly in patients with cancers such as lung or breast cancer. It results from delayed fibrosis and nerve injury in the irradiated field. The injury mechanism involves chronic radiation-induced fibrosis leading to microvascular damage and subsequent ischemia of the nerve fibers within the brachial plexus. This results in slowly progressive neuropathic changes, often detected as fibrillations on EMG/NCS studies. Unlike inflammatory or neoplastic plexopathies, this condition is characterized by non-inflammatory, fibrotic changes. In the presented case, a patient with a history of lung cancer treated with radiation 6 months ago now develops shoulder discomfort and weakness (notably in shoulder abduction and elbow flexion). EMG findings showing fibrillation potentials in the hands and forearm muscles are consistent with radiation-induced nerve injury. The absence of acute changes or tumor recurrence on imaging directs attention toward a noninvasive, supportive management strategy. Diagnosis is clinical and electrophysiological. NCS/EMG are utilized to document the extent and nature of the nerve damage. Differential diagnoses include recurrent tumor invasion (which usually would have imaging correlates), inflammatory brachial plexitis, and compressive neuropathies. An MRI may be considered if the diagnosis remains uncertain or if there is suspicion of tumor recurrence. Management is predominantly conservative. First-line treatment involves symptomatic care, including physical therapy to maintain function and prevent contractures. Pain control using neuropathic agents may be utilized as needed. There is no role for surgical exploration, corticosteroids, or further radiation in a confirmed case of radiation-induced plexopathy. In pregnant or lactating patients, non-pharmacological interventions (physical therapy, occupational therapy) are preferred, and any medications used for pain should be reviewed for safety according to current obstetric guidelines. Option A (immediate surgical exploration or biopsy) is incorrect because the condition is non-surgical. Option B (supportive management without further invasive intervention) is correct\u2014as it implies no aggressive treatment is needed beyond symptom management. Options involving chemotherapy or steroids are inappropriate because they do not address the fibrotic, non-inflammatory nature of radiation-induced injury. 1. Radiation-induced plexopathy typically presents months after radiation with insidious onset of pain and weakness. 2. Electrophysiological studies help differentiate it from tumor recurrence. 3. Management is supportive; early physical therapy is key to preserving function. Current guidelines and recent studies affirm that the management of radiation-induced plexopathy is supportive. There is no evidence to support the use of corticosteroids or surgical interventions in these cases. Research continues to explore methods to minimize radiation-induced nerve damage, emphasizing preventive measures and early rehabilitative care.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Poorly controlled DM1 type 1, hg A1c 14, become controled one week started to complain of pain",
    "option_a": "(Gabapentin) is correct and is supported by evidence as a first",
    "option_b": "(Steroid) is incorrect because steroids are not indicated and may worsen glycemic control. Option C (Skin biopsy) is a diagnostic tool for small fiber neuropathy and is not a therapeutic intervention. Option D (Nerve biopsy) is invasive and inappropriate in cases of typical diabetic neuropathy.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Painful diabetic neuropathy is a common complication of diabetes mellitus, particularly in poorly controlled patients. It involves chronic neuropathic pain resulting from nerve damage associated with long-standing hyperglycemia. Persistent hyperglycemia leads to metabolic and microvascular changes that damage peripheral nerves, particularly small fibers. The resultant neuropathy manifests as burning, tingling, and pain. Gabapentin, a calcium channel modulator, is effective in reducing neuropathic pain by dampening neuronal excitability. A patient with a history of poorly controlled type 1 diabetes (hemoglobin A1c of 14) who, after improved glycemic control, begins to experience neuropathic pain fits the typical presentation of painful diabetic neuropathy. This condition is primarily sensory, with pain being the predominant complaint. While the diagnosis of diabetic neuropathy is largely clinical, additional tests such as nerve conduction studies or quantitative sensory testing can be used. Differential diagnoses include other causes of neuropathy such as vitamin B12 deficiency, alcohol-induced neuropathy, or hypothyroidism, which can be clarified with appropriate laboratory testing. First-line management for painful diabetic neuropathy involves the use of anticonvulsants such as gabapentin or pregabalin to reduce neuropathic pain. Second-line agents include serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine. For pregnant or lactating patients, medication choice should be carefully considered\u2014gabapentin is a Category C drug and may be used if the benefits outweigh the risks, but non-pharmacologic therapies should also be emphasized and coordinated with obstetric guidance. Option A (Gabapentin) is correct and is supported by evidence as a first-line agent for neuropathic pain in diabetic neuropathy. Option B (Steroid) is incorrect because steroids are not indicated and may worsen glycemic control. Option C (Skin biopsy) is a diagnostic tool for small fiber neuropathy and is not a therapeutic intervention. Option D (Nerve biopsy) is invasive and inappropriate in cases of typical diabetic neuropathy. 1. Tight glycemic control is important, but rapid changes may unmask neuropathic pain. 2. Gabapentin is one of the primary medications for managing painful diabetic neuropathy. 3. Always evaluate for other causes of neuropathy in diabetic patients. Recent clinical guidelines and meta-analyses support the use of gabapentin as a first-line treatment for painful diabetic neuropathy, with numerous randomized controlled trials demonstrating its efficacy. Ongoing research is examining optimal dosing regimens and long-term outcomes, and current practice emphasizes individualized treatment planning, especially in special populations such as pregnant or lactating women.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Lady with history of breast cancer treated, came with one week hx of 4th and 5th digit numbness, and weakness in hand and forearm I believe, pain, chest and neck ct normal what to do next",
    "option_a": "(Plexus MRI) is not the immediate next step because structural imaging, while useful, is less sensitive than electrophysiological studies in detecting functional nerve impairments. Option B (NCS/EMG) is correct, as these studies provide direct information on nerve function and can differentiate various causes of neuropathy. Option C (PET scan) is generally reserved for identifying metabolically active tumor recurrence rather than evaluating nerve function, making it an inappropriate first choice in this setting.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "In patients with a history of breast cancer, new onset of upper limb neurological symptoms warrants careful evaluation for brachial plexopathy. This may be due to radiation-induced changes, tumor recurrence, or unrelated peripheral nerve pathology. Brachial plexopathy can result from radiation-induced fibrosis, direct tumor infiltration, or paraneoplastic processes. Radiation-induced plexopathy typically manifests as an insidious onset of pain, sensory disturbances, and motor weakness in a distribution that corresponds to the affected portion of the plexus. In this case, symptoms affecting the 4th and 5th digits suggest involvement of the lower trunk of the plexus. The patient\u2019s presentation with numbness in the 4th and 5th digits, along with weakness in the hand and forearm, is consistent with a lower brachial plexus involvement. The fact that chest and neck CT scans are normal reduces the likelihood of overt tumor recurrence and favors a functional assessment of nerve conduction. The next appropriate step is to perform nerve conduction studies (NCS) and electromyography (EMG) to localize and characterize the lesion. Differential diagnoses include cervical radiculopathy, entrapment neuropathies (such as ulnar neuropathy), and radiation-induced brachial plexopathy. NCS/EMG helps to differentiate these conditions by assessing nerve conduction velocities, amplitude, and the pattern of denervation. Once the diagnosis is confirmed with NCS/EMG, management is largely supportive. First-line treatment includes physical therapy, occupational therapy, and pain management strategies (with agents such as gabapentin or pregabalin, if needed). In pregnant or lactating women, non-pharmacologic management is prioritized and any medications used should be thoroughly evaluated for safety in these populations according to current guidelines. Option A (Plexus MRI) is not the immediate next step because structural imaging, while useful, is less sensitive than electrophysiological studies in detecting functional nerve impairments. Option B (NCS/EMG) is correct, as these studies provide direct information on nerve function and can differentiate various causes of neuropathy. Option C (PET scan) is generally reserved for identifying metabolically active tumor recurrence rather than evaluating nerve function, making it an inappropriate first choice in this setting. 1. NCS/EMG is the gold standard for evaluating suspected brachial plexopathy and can help differentiate between radiation-induced changes and other etiologies. 2. In patients with a history of breast cancer, always consider both radiation-induced injury and tumor recurrence in the differential. 3. Early electrophysiological evaluation can guide appropriate management and avoid unnecessary invasive procedures. Recent guidelines emphasize the role of electrodiagnostic studies in the early evaluation of brachial plexopathies, especially in patients with a history of cancer. Advances in neurophysiologic techniques continue to refine our ability to localize lesions and distinguish between different etiologies, supporting the current practice of using NCS/EMG as the next step when imaging studies are unrevealing.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient has myotonia symptoms since age 10 for 5 years, father had myotonia, no mention of weakness, what",
    "option_a": "(Thomsen disease) is correct because it aligns with the patient\u2019s presentation: childhood onset, isolated myotonia without weakness, and a positive family history suggesting autosomal dominant inheritance. In contrast, myotonic dystrophy (a potential distractor) would typically present with weakness, systemic features, and a different inheritance pattern, and the recessive Becker variant is usually associated with some degree of weakness.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Thomsen disease is a form of non-dystrophic myotonia, specifically the autosomal dominant type of myotonia congenita. It typically begins in childhood with muscle stiffness (myotonia) but without significant weakness, which contrasts with other myotonic disorders that may present with multisystem or progressive weakness. Thomsen disease is caused by mutations in the CLCN1 gene that encodes the skeletal muscle chloride channel. The defect results in impaired chloride conductance, leading to delayed repolarization of the muscle cell membrane and prolonged muscle contraction (myotonia). The autosomal dominant pattern is evident from the positive family history, as seen with the affected father. Patients usually present in childhood with complaints of muscle stiffness that improves with repeated movement (the so\u2010called warm-up phenomenon). The absence of weakness and systemic features helps differentiate it from disorders like myotonic dystrophy, which involves not only myotonia but also progressive weakness and multisystem involvement (e.g., cataracts, cardiac conduction abnormalities). Diagnosis is supported by detailed clinical history, family history, and electromyography (EMG) showing characteristic myotonic discharges. Differential diagnoses include myotonic dystrophy (typically with systemic involvement and additional signs like facial weakness and cataracts), paramyotonia congenita (with cold-induced symptoms), and other channelopathies. Genetic testing for CLCN1 mutations can provide definitive confirmation. Management is primarily symptomatic. First-line treatment often includes sodium channel blockers such as mexiletine to reduce myotonia. Other options include medications like lamotrigine or carbamazepine. In the context of pregnancy and lactation, the potential risks and benefits of these medications must be weighed carefully; for example, mexiletine is usually considered if the benefits outweigh the potential fetal risks, and consultation with a maternal\u2010fetal medicine specialist is recommended. Physical therapy and supportive management also form part of the care plan. Option a (Thomsen disease) is correct because it aligns with the patient\u2019s presentation: childhood onset, isolated myotonia without weakness, and a positive family history suggesting autosomal dominant inheritance. In contrast, myotonic dystrophy (a potential distractor) would typically present with weakness, systemic features, and a different inheritance pattern, and the recessive Becker variant is usually associated with some degree of weakness. 1. Thomsen disease presents with isolated myotonia and minimal weakness with an autosomal dominant pattern. 2. The warm-up phenomenon is a key clinical sign. 3. Genetic testing for CLCN1 mutations confirms the diagnosis. Recent studies continue to support the use of mexiletine as the first-line treatment for myotonia. Genetic and molecular research is ongoing to better understand channelopathies, and current guidelines emphasize individualized management including genetic counseling for affected families.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario about botulism with increment on high frequency RNS what pathology",
    "option_a": ", 'Prevent acetylcholine release from presynaptic vesicles', is correct because it accurately describes the mechanism of botulinum toxin. Alternate mechanisms such as postsynaptic receptor blockade or muscle fiber membrane instability do not account for the electrophysiological findings (increment on high",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Botulism is a neuroparalytic illness caused by a toxin produced by Clostridium botulinum. The toxin specifically interferes with neuromuscular transmission, leading to a characteristic descending paralysis. Botulinum toxin cleaves SNARE proteins which are essential for the fusion of acetylcholine-containing vesicles with the presynaptic membrane at the neuromuscular junction. The blockade of acetylcholine release results in impaired neuromuscular transmission. Electrophysiologically, with high-frequency repetitive nerve stimulation (RNS), there is a facilitation (increment) due to the calcium accumulation in nerve terminals, temporarily overcoming the blockade. Clinically, botulism presents with symptoms such as blurred vision, dysphagia, and a descending flaccid paralysis. The facilitation seen on high-frequency RNS helps differentiate it from disorders such as myasthenia gravis, which typically shows decrement without facilitation, and Lambert\u2013Eaton myasthenic syndrome, which also shows facilitation but has a distinct clinical presentation. Diagnosis hinges on clinical history (e.g., potential ingestion of contaminated food or wound exposure), neurological examination, and electrophysiological studies. Differential diagnoses include myasthenia gravis (which affects postsynaptic receptors and exhibits a decremental response on low-frequency stimulation) and Lambert-Eaton Myasthenic Syndrome (which, although showing an incremental response, is associated with underlying malignancy and autonomic symptoms). Management of botulism is largely supportive, with prompt administration of botulinum antitoxin being the mainstay of therapy to neutralize circulating toxin. Intensive care support, including respiratory support, is often necessary due to the risk of respiratory failure. In pregnant or lactating patients, antitoxin administration is still recommended as the benefit (preventing further toxin spread and paralysis) outweighs potential risks, and there is no known teratogenic effect associated with its use. Option a, 'Prevent acetylcholine release from presynaptic vesicles', is correct because it accurately describes the mechanism of botulinum toxin. Alternate mechanisms such as postsynaptic receptor blockade or muscle fiber membrane instability do not account for the electrophysiological findings (increment on high-frequency RNS) seen in botulism. 1. Botulism leads to a descending paralysis due to presynaptic inhibition of acetylcholine release. 2. Facilitation on high-frequency RNS is an electrophysiological hallmark. 3. Early antitoxin administration is critical for patient outcomes. Contemporary guidelines emphasize early recognition and treatment with antitoxin along with intensive supportive care. Research continues to evaluate optimal dosing strategies for antitoxin and adjunctive treatments, with regulatory bodies like the CDC and FDA providing updated recommendations based on emerging data.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "20 yr with respiratory symptoms, aneurysm, PAS on pathology, neg forearm exercise dx, no clinical but electrical myotonia",
    "option_a": "(Pompe disease) is correct because the clinical features\u2014PAS",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Pompe disease, also known as Glycogen Storage Disease Type II, is a metabolic myopathy caused by a deficiency of acid alpha-glucosidase. It presents in a spectrum ranging from infantile to late-onset forms, with the late-onset form typically characterized by progressive muscle weakness and respiratory involvement. The enzyme deficiency leads to inadequate breakdown of glycogen, causing its accumulation within lysosomes. This accumulation disrupts normal muscle fiber architecture and function. In late-onset Pompe disease, there can be the presence of electrical myotonia on EMG studies without overt clinical myotonia, reflecting subcellular changes in the muscle fibers. The described 20-year-old patient presents with respiratory symptoms and muscle biopsy findings (PAS-positive glycogen accumulation) that are strongly indicative of Pompe disease. A negative forearm exercise test helps to exclude conditions like McArdle disease (GSD V), which typically shows abnormal results due to a deficiency in muscle phosphorylase. The presence of electrical myotonia, though without clinical myotonia, is an electrophysiological finding that can be seen in Pompe disease. Diagnosis is based on a combination of clinical history, muscle biopsy demonstrating PAS-positive vacuoles filled with glycogen, and enzyme assays showing decreased acid alpha-glucosidase activity. Differential diagnoses include McArdle disease (which usually shows exercise intolerance and a positive forearm exercise test) and myotonic dystrophy (which has additional systemic findings and clinical myotonia). The cornerstone of treatment is enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase (alglucosidase alfa). Supportive care including respiratory support and physical therapy is critical. In pregnancy and lactation, while data are limited, ERT should be considered if the benefits outweigh potential risks; management should involve a multidisciplinary team including metabolic specialists and maternal-fetal medicine experts. Option a (Pompe disease) is correct because the clinical features\u2014PAS-positive glycogen deposits on muscle biopsy, respiratory symptoms, a negative forearm exercise test (which excludes McArdle disease), and the presence of electrical myotonia\u2014are all consistent with Pompe disease. Other options like McArdle disease or myotonic dystrophy do not fit this combination of findings. 1. Pompe disease should be suspected in young patients with respiratory involvement and PAS-positive glycogen accumulation on biopsy. 2. Electrical myotonia in the absence of clinical myotonia is a subtle but important diagnostic clue. 3. A negative forearm exercise test helps differentiate Pompe disease from other glycogen storage disorders like McArdle disease. Recent guidelines and studies have reinforced the importance of early initiation of ERT to improve survival and quality of life in patients with Pompe disease. Ongoing research into gene therapy and novel adjunctive treatments may further expand therapeutic options in the future.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Infant with respiratory, electrical myotonia, macroglosia",
    "option_a": "(Pompe disease) is correct as it best fits the clinical triad in the infant: respiratory distress, macroglossia, and electrical myotonia. Other options like myotonic dystrophy, congenital myasthenic syndromes, or spinal muscular atrophy do not present with the combination of severe infantile respiratory failure and macroglossia along with PAS",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Infantile Pompe disease is a glycogen storage disorder resulting from a deficiency of acid alpha-glucosidase. This enzyme defect leads to the accumulation of glycogen in various tissues, notably in cardiac and skeletal muscles, manifesting during infancy. The failure to degrade lysosomal glycogen leads to its accumulation within muscle cells, causing cellular damage and dysfunction. In infants, this manifests as profound muscle weakness, respiratory distress, and macroglossia. Electrical myotonia seen on EMG reflects underlying alterations in muscle fiber excitability secondary to glycogen accumulation. Infants with Pompe disease typically present with respiratory failure, feeding difficulties, hypotonia, and macroglossia. The combination of these clinical signs alongside supportive laboratory findings (such as PAS-positive deposits on muscle biopsy) is highly characteristic. The presence of electrical myotonia further supports the diagnosis despite the absence of overt clinical myotonia. The diagnosis is made based on clinical findings, confirmed by muscle biopsy (revealing PAS-positive vacuoles) and enzyme assay demonstrating deficient acid alpha-glucosidase activity. Differential diagnoses include congenital myasthenic syndromes (which show fatigable weakness without glycogen accumulation) and spinal muscular atrophy (which lacks features like macroglossia and PAS positivity). The mainstay of treatment is enzyme replacement therapy (ERT) with alglucosidase alfa, which has been shown to improve survival and motor outcomes if initiated early. Supportive care, including respiratory support and nutritional management, is crucial. There are limited data on ERT in pregnant or lactating patients; however, if a pregnant mother is affected by Pompe disease, continuation of therapy is generally recommended under close specialist supervision, as untreated disease poses significant risks. Option a (Pompe disease) is correct as it best fits the clinical triad in the infant: respiratory distress, macroglossia, and electrical myotonia. Other options like myotonic dystrophy, congenital myasthenic syndromes, or spinal muscular atrophy do not present with the combination of severe infantile respiratory failure and macroglossia along with PAS-positive glycogen accumulation on biopsy. 1. Infantile Pompe disease is a life\u2010threatening condition that requires early diagnosis and treatment. 2. Macroglossia in an infant is an important clinical clue toward Pompe disease. 3. Enzyme replacement therapy has dramatically improved the prognosis for affected infants. Current research supports the early use of ERT to mitigate the progressive nature of Pompe disease. Updated guidelines from metabolic and neuromuscular societies recommend prompt diagnosis and initiation of therapy. Ongoing clinical trials investigating gene therapy could further expand future treatment options.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Ocular muscle weakness, ptosis with Mild facial weakness, proximal weakness",
    "option_a": "(GCG repeat expansion) is correct as it directly explains the genetic basis of OPMD. Other options suggesting mitochondrial mutations, autoimmune myasthenia gravis, distal myopathies, or inflammatory myopathies do not fit the typical distribution of weakness (ocular, facial, and proximal) or the established genetic mutation.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscular dystrophy characterized by progressive ptosis, dysphagia, mild facial weakness, and proximal limb weakness. The core concept centers on a specific genetic mechanism affecting muscle function. OPMD results from a trinucleotide (GCG) repeat expansion in the PABPN1 gene. The abnormal expansion leads to misfolding of the nuclear polyadenylate-binding protein and results in the accumulation of insoluble protein aggregates in the muscle fibers, eventually causing muscle fiber degeneration. Up\u2010to\u2010date evidence supports that these aggregates interfere with normal muscle cell metabolism and function. The clinical picture of ptosis and ocular muscle involvement, coupled with proximal weakness and mild facial muscle involvement, is classic for OPMD. The phenotype is recognized by its gradual onset typically in middle or late adulthood, and family history often reveals an autosomal dominant inheritance pattern. Diagnosis is based on clinical history, physical examination, and confirmation through genetic testing for the GCG repeat expansion in the PABPN1 gene. Differential diagnoses to consider include myasthenia gravis (which presents with fluctuating and fatigable weakness), mitochondrial myopathies (with multisystem involvement), and inflammatory myopathies (which usually have prominent inflammatory markers and different biopsy findings). There is currently no curative treatment for OPMD. Management focuses on symptomatic relief such as surgical correction of ptosis, swallowing therapies and nutritional support, and physical therapy to maintain muscle strength. In the context of pregnancy and lactation, management remains supportive; medications should be used with caution and in consultation with neuromuscular as well as obstetric specialists to avoid potential iatrogenic complications. Option a (GCG repeat expansion) is correct as it directly explains the genetic basis of OPMD. Other options suggesting mitochondrial mutations, autoimmune myasthenia gravis, distal myopathies, or inflammatory myopathies do not fit the typical distribution of weakness (ocular, facial, and proximal) or the established genetic mutation. 1) OPMD typically presents in the 5th to 6th decade of life with ptosis and dysphagia. 2) Family history is frequently positive due to autosomal dominant transmission. 3) Genetic testing for GCG expansions in PABPN1 is diagnostic. Recent guidelines emphasize the role of genetic confirmation in neuromuscular disorders. Research is ongoing into therapies aimed at reducing protein aggregates and correcting the underlying genetic defect, although current management remains supportive.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Neuromyopathies, asking about the medications",
    "option_a": "(Chloroquine) is correct because it is uniquely associated with lysosomal dysfunction leading to vacuolar myopathy. Other medications such as corticosteroids or statins produce distinct pathological changes that do not involve autophagic vacuoles, making them less likely causes of the scenario described.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Medication-induced myopathy represents an important category of neuromyopathies. Chloroquine is a classic causative agent because of its unique ability to disrupt lysosomal function in muscle cells. Chloroquine accumulates in lysosomes, leading to lysosomal dysfunction and impaired autophagic flux. This results in the formation of autophagic vacuoles and curvilinear bodies within muscle fibers, causing muscle fiber damage and necrosis. The pathology observed on muscle biopsy is distinct from that seen with other agents. Clinically, patients who develop chloroquine-induced myopathy present with a gradual onset of proximal muscle weakness. The characteristic biopsy finding of autophagic vacuoles supports the diagnosis, especially when correlated with a history of chronic chloroquine or chloroquine-analogue use. The differential diagnoses include corticosteroid-induced myopathy (which generally shows type II fiber atrophy rather than vacuolar changes), statin-induced necrotizing myopathy (which typically features necrosis without significant vacuolar formation), and inflammatory myopathies (which are characterized by inflammatory infiltrates). A detailed medication history and muscle biopsy are critical for accurate diagnosis. Management involves immediate discontinuation of the offending agent (chloroquine) and supportive care including physical therapy. Recovery is generally gradual after cessation of the drug. In pregnancy and lactation, chloroquine should be used only if the benefits outweigh the risks; in cases of adverse effects, alternative medications should be considered with appropriate consultation from obstetric specialists. Option a (Chloroquine) is correct because it is uniquely associated with lysosomal dysfunction leading to vacuolar myopathy. Other medications such as corticosteroids or statins produce distinct pathological changes that do not involve autophagic vacuoles, making them less likely causes of the scenario described. 1) Always review medication histories in patients presenting with new-onset muscle weakness. 2) Vacuolar changes on muscle biopsy are a hallmark of chloroquine toxicity. 3) Early recognition and drug discontinuation are key to recovery. Recent studies continue to support the association between chloroquine use and vacuolar myopathy with characteristic biopsy findings. Updated guidelines recommend regular monitoring of muscle strength in patients on long-term chloroquine therapy.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario or hypokalemic PP, low K 2.3 treated asking about tx",
    "option_a": "",
    "option_b": "",
    "option_c": "(Daily potassium supplementation) is correct because it directly addresses the hypokalemia that underlies HypoPP. Acetazolamide (option a) is used prophylactically rather than for acute management, and spironolactone (option b) is not established as an effective treatment in this condition.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuromuscular",
    "explanation": "Hypokalemic periodic paralysis (HypoPP) is an episodic neuromuscular disorder marked by sudden-onset muscle weakness and paralysis in the context of low serum potassium levels. The condition is often genetically mediated, affecting ion channels in the muscle membrane. HypoPP is typically due to mutations in voltage-gated ion channels (such as CACNA1S or SCN4A) that disturb the regulation of potassium and membrane excitability. During an attack, triggers like a carbohydrate-rich meal or strenuous exercise precipitate an abnormal shift of potassium into cells, leading to severe hypokalemia and subsequent muscle membrane inexcitability. Patients present with episodes of weakness or paralysis that can vary from mild to severe. The attacks often affect the proximal muscles more profoundly. The serum potassium during attacks is markedly low (around 2.3 mEq/L in this scenario), which is diagnostic. Differential diagnoses include hyperkalemic periodic paralysis (which has a distinct potassium profile), thyrotoxic periodic paralysis (which must be excluded by thyroid function tests), and other causes of acute paralysis (such as Guillain\u2013Barr\u00e9 syndrome). Serum electrolytes, a detailed history, and, when indicated, genetic testing, are key to confirming the diagnosis. The acute management of HypoPP involves immediate correction of hypokalemia using oral or intravenous potassium supplementation. Daily oral potassium supplementation is the mainstay during acute attacks and can sometimes be used for chronic prophylaxis. Long-term management may also include trigger avoidance and, in some cases, prophylactic medications such as low-dose acetazolamide (although not for acute treatment). In pregnancy and lactation, oral potassium supplementation is generally safe but should be administered under careful medical supervision, with dose adjustments as needed and multidisciplinary oversight. Option c (Daily potassium supplementation) is correct because it directly addresses the hypokalemia that underlies HypoPP. Acetazolamide (option a) is used prophylactically rather than for acute management, and spironolactone (option b) is not established as an effective treatment in this condition. 1) Rapid potassium replacement is essential for reversing muscle paralysis in HypoPP. 2) Prophylactic measures (such as avoiding high-carb meals) are important in long-term management. 3) Genetic confirmation can aid in subtype identification and tailoring therapy. Recent clinical guidelines underscore the importance of immediate potassium repletion during attacks, and ongoing research is evaluating genotype-specific responses to prophylactic therapies like acetazolamide. Updated recommendations continue to support the role of oral potassium supplementation as first-line treatment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient on statin had necrotizing myositis whats the cause",
    "option_a": "",
    "option_b": "(Erythromycin interaction) is correct because it specifically identifies the pharmacokinetic mechanism that raises statin levels, leading to a higher risk of necrotizing myopathy. Option a (age) does not directly cause necrotizing myositis, though older age may predispose patients to drug toxicity, it is not the precipitating cause in this scenario.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Statin-induced myopathy is a recognized adverse effect of statin therapy. This myopathy can progress to a necrotizing form, particularly when statin levels become supra-therapeutic, such as when they interact with other medications. Erythromycin, a potent CYP3A4 inhibitor, interferes with the metabolism of certain statins, leading to elevated plasma concentrations. The increased statin level can cause direct myotoxic effects resulting in muscle fiber necrosis, inflammation, and, in severe cases, necrotizing myopathy. Patients on statin therapy who develop muscle pain, weakness, and elevated creatine kinase (CK) levels may be experiencing statin-induced myopathy. When this myopathy progresses to a necrotizing pattern, it suggests a more severe muscle injury often linked to an external precipitant such as a drug interaction. In this case, concurrent use of erythromycin is a classic risk factor. Differential diagnoses include autoimmune necrotizing myopathy, rhabdomyolysis from other causes, and other drug-induced myopathies. The diagnosis is supported by laboratory studies (elevated CK), a detailed medication history indicating potential interactions, and in some cases, muscle biopsy showing necrosis without significant inflammatory infiltrate. The primary management step is discontinuing the statin and the interacting agent (erythromycin in this scenario). Alternative lipid-lowering therapies may be considered after recovery, especially in patients at high cardiovascular risk. In pregnancy and lactation, statins are contraindicated due to their teratogenic potential, so alternative management strategies such as lifestyle modification and non-statin therapies should be employed. Option b (Erythromycin interaction) is correct because it specifically identifies the pharmacokinetic mechanism that raises statin levels, leading to a higher risk of necrotizing myopathy. Option a (age) does not directly cause necrotizing myositis, though older age may predispose patients to drug toxicity, it is not the precipitating cause in this scenario. 1) Always check for drug interactions in patients on statin therapy, especially with CYP3A4 inhibitors like erythromycin. 2) Markedly elevated CK levels in a patient on statins warrant investigation for myopathy. 3) Statin-induced myopathy can escalate to severe necrotizing myopathy if precipitated by drug interactions. Recent reviews and guideline updates have highlighted the risk of CYP3A4 inhibitors (including erythromycin) in exacerbating statin toxicity. Newer lipid-lowering agents and revised dosing strategies are being considered to minimize the risk of myopathy, particularly in patients requiring concomitant medications.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Moderate muscle weakness, hyperkeratosis on the hand lung crackles",
    "option_a": "(MDA",
    "option_b": "(anti",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a patient with moderate muscle weakness, hyperkeratosis on the hands (commonly referred to as mechanic's hands), and lung crackles. These findings are classic for an inflammatory myopathy with pulmonary involvement, particularly anti\u2010synthetase syndrome, which is a subset of the idiopathic inflammatory myopathies. Anti-synthetase syndrome is mediated by autoantibodies against aminoacyl-tRNA synthetases (most frequently anti-Jo-1). These antibodies trigger an immune-mediated inflammatory process affecting skeletal muscle and lung parenchyma. In contrast, anti-MDA-5 antibodies are more often found in clinically amyopathic dermatomyositis where skin ulcerations and rapidly progressive interstitial lung disease predominate, but with only minimal or absent muscle involvement. Patients with anti-synthetase syndrome typically present with a triad: inflammatory myopathy (evidenced by moderate muscle weakness), cutaneous findings such as mechanic's hands (hyperkeratotic, cracked skin on the lateral aspects of the fingers), and interstitial lung disease (manifesting as lung crackles on auscultation). This constellation of findings links the pathophysiologic immune attack to the clinical presentation. The evaluation involves serologic testing for myositis-specific antibodies. The presence of anti-synthetase antibodies (e.g., anti-Jo-1) supports the diagnosis. Differential diagnoses include polymyositis, dermatomyositis (especially the MDA-5 variant), and other connective tissue diseases with lung involvement. High-resolution chest CT and pulmonary function tests are useful in delineating the lung involvement. First-line management typically involves high-dose corticosteroids to manage both myositis and interstitial lung disease. Adjunct immunosuppressive agents such as methotrexate, azathioprine, or mycophenolate mofetil are often added for a steroid-sparing effect. In refractory cases, therapies like rituximab may be considered. In pregnant or lactating patients, corticosteroids and azathioprine may be used with caution, whereas methotrexate is contraindicated. Close monitoring of pulmonary status is essential. Option a (MDA-5 antibody) is incorrect because it is typically associated with a form of dermatomyositis that presents with minimal muscle weakness, prominent skin ulcerations, and rapidly progressive lung disease. Option b (anti-synthetase antibody) is correct as it corresponds to anti-synthetase syndrome, which aligns with the clinical features described. 1) Mechanic's hands are a hallmark feature of anti-synthetase syndrome. 2) Anti-Jo-1 is the most common anti-synthetase antibody. 3) Interstitial lung disease is a major contributor to morbidity in these patients. Recent research underscores the benefit of early diagnosis and aggressive immunosuppressive therapy to slow the progression of lung disease. Multidisciplinary management involving rheumatologists, pulmonologists, and neurologists is recommended to improve outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario patient has progressive hand muscle weakness with severe atrophy, planters upgoing in LL dx",
    "option_a": "(ALS) is correct as it best explains the mixed upper and lower motor neuron involvement observed in the patient. Other options like myelitis or myelopathy are less fitting since they would typically present with sensory deficits or a different pattern of progression.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical scenario describes progressive hand muscle weakness with severe atrophy (indicative of lower motor neuron involvement) combined with upgoing plantar responses in the lower limbs (a sign of upper motor neuron involvement). This combination is characteristically seen in amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative disorder affecting both upper (corticospinal tracts) and lower motor neurons (anterior horn cells). The degeneration leads to muscle denervation, atrophy, spasticity, and hyperreflexia. The coexistence of UMN and LMN signs in one region (e.g., the hands) is critical for the diagnosis. Patients with ALS typically present with focal muscle weakness that evolves into a more widespread pattern. The presence of severe atrophy and fasciculations (LMN signs) along with hyperreflexia and an extensor plantar response (UMN signs) strongly suggests ALS. Sensory modalities remain intact, differentiating it from many other neurological conditions. The diagnostic workup includes clinical evaluation, electromyography (EMG) demonstrating denervation and reinnervation patterns, and ruling out structural lesions with MRI of the brain and cervical spine. Differential diagnoses include cervical myelopathy, multifocal motor neuropathy, and other motor neuron diseases such as primary lateral sclerosis, which involves only UMN signs. Management of ALS is largely supportive and multidisciplinary. Riluzole is the first-line medication as it can modestly extend survival. Edaravone is another FDA-approved treatment that may slow disease progression in selected patients. Symptom management, including physical therapy, speech therapy, and nutritional support, is essential. In pregnant patients, the use of riluzole requires a careful risk-benefit analysis (categorized as pregnancy category C) and should involve specialized counseling. Option a (ALS) is correct as it best explains the mixed upper and lower motor neuron involvement observed in the patient. Other options like myelitis or myelopathy are less fitting since they would typically present with sensory deficits or a different pattern of progression. 1) The coexistence of UMN and LMN signs in the same region is a key diagnostic clue for ALS. 2) EMG is essential in confirming the diagnosis. 3) ALS predominantly spares sensory functions. Recent guidelines emphasize a multidisciplinary approach to ALS management. While riluzole remains the mainstay of pharmacologic treatment, emerging therapies and supportive care strategies continue to be evaluated in clinical trials to improve quality of life and survival.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario suggest of Periodic paralysis (filipino guy with generalized muscle weakness) asking about next investigation",
    "option_a": "(serum potassium level measurement) is correct because it is the cornerstone diagnostic test in periodic paralysis, allowing for immediate determination of the type (hypokalemic vs hyperkalemic) and guiding subsequent management decisions. Other tests such as serum calcium/magnesium levels, EMG, genetic testing, or muscle biopsy do not provide the rapid, actionable information that serum potassium does.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Periodic paralysis is a neuromuscular disorder characterized by sudden onset episodes of muscle weakness due to transient alterations in serum potassium levels. The primary diagnostic consideration in an acute attack is determining the serum potassium concentration. Periodic paralysis often arises from mutations that affect ion channels in muscle membranes. In hypokalemic periodic paralysis, low serum potassium levels lead to reduced muscle excitability and episodes of weakness. Conversely, hyperkalemic periodic paralysis involves high serum potassium levels, though both types are related to ion channel dysfunction. During an attack, patients present with generalized, often profound, muscle weakness that may mimic other neuromuscular conditions. The measurement of serum potassium during an episode is critical since it directly guides management. The history and demographic factors (for example, certain ethnic predispositions) can provide additional clues. The initial workup involves an immediate serum potassium level measurement. Differential diagnoses include conditions such as myasthenic crisis, Guillain-Barr\u00e9 syndrome, and metabolic myopathies. However, none of these conditions are characterized by acute reversible potassium disturbances, making serum potassium a discriminating test. Management during an acute attack depends on the potassium level: Hypokalemic attacks are managed with careful potassium supplementation and avoidance of triggers such as high-carbohydrate meals, while hyperkalemic attacks require measures to lower serum potassium. Long-term management may involve carbonic anhydrase inhibitors. In pregnant or lactating patients, electrolyte replacement should be done cautiously under close monitoring, ensuring both maternal and fetal safety. Option a (serum potassium level measurement) is correct because it is the cornerstone diagnostic test in periodic paralysis, allowing for immediate determination of the type (hypokalemic vs hyperkalemic) and guiding subsequent management decisions. Other tests such as serum calcium/magnesium levels, EMG, genetic testing, or muscle biopsy do not provide the rapid, actionable information that serum potassium does. 1) Always measure serum potassium during an attack of periodic paralysis. 2) The type of periodic paralysis (hypokalemic or hyperkalemic) determines the treatment strategy. 3) Triggers such as carbohydrate-rich meals can precipitate hypokalemic attacks. Recent studies support the use of genetic testing for long-term management after biochemical confirmation. Current guidelines stress the importance of early potassium correction and avoidance of known triggers to prevent recurrent episodes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario about dysferlin CK up35X, mild upper limb weakness mainly LL and significant calf atrophy weak dorsiflexion dx",
    "option_a": "(Myoshi myopathy/LGMD2B) is correct because the constellation of clinical signs (distal weakness, calf atrophy, elevated CK) and the typical pattern of dysferlin gene involvement point directly to this diagnosis. Other options like Duchenne, Becker, or facioscapulohumeral muscular dystrophy do not match the clinical distribution or laboratory findings as precisely.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a patient with significantly elevated creatine kinase levels (>35 times normal), mild upper limb weakness with predominant lower limb involvement, significant calf atrophy, and weak dorsiflexion. These features are characteristic of a dysferlinopathy, specifically Miyoshi myopathy (LGMD2B). Dysferlinopathy is caused by mutations in the dysferlin gene, leading to defective muscle membrane repair and progressive muscle fiber degeneration. The condition frequently manifests as distal muscle weakness and marked calf muscle atrophy. The significant rise in CK reflects ongoing muscle damage. Patients with Miyoshi myopathy typically exhibit early involvement of the distal muscles of the lower limbs, such as the calves (resulting in marked atrophy) and dorsiflexors. Upper limb weakness may be present but is generally mild. The pattern of weakness along with a high CK level aids in differentiating this condition from other muscular dystrophies. The diagnosis is supported by clinical examination, markedly elevated CK levels, and confirmed by genetic testing and/or muscle biopsy with immunohistochemical staining for dysferlin. Differential diagnoses include Duchenne and Becker muscular dystrophies, which typically present with proximal weakness and different age of onset, as well as facioscapulohumeral muscular dystrophy, which involves facial and scapular muscles rather than predominantly distal lower limb muscles. There is no definitive cure for dysferlinopathy. Management is primarily supportive, focusing on physical therapy, orthopedic interventions to manage contractures, and maintaining mobility. Current research is exploring gene therapies. For pregnant or lactating patients, supportive care including physical therapy is safe, and genetic counseling is recommended. Option a (Myoshi myopathy/LGMD2B) is correct because the constellation of clinical signs (distal weakness, calf atrophy, elevated CK) and the typical pattern of dysferlin gene involvement point directly to this diagnosis. Other options like Duchenne, Becker, or facioscapulohumeral muscular dystrophy do not match the clinical distribution or laboratory findings as precisely. 1) Markedly elevated CK levels are common in dysferlinopathies. 2) The pattern of predominant distal lower limb weakness with significant calf atrophy is a key clinical clue. 3) Genetic testing is essential for a definitive diagnosis. Recent advances in molecular genetics have improved the diagnostic accuracy for dysferlinopathies. Although no cure exists, emerging gene therapy trials offer hope for future treatment options. Current guidelines emphasize supportive care and multidisciplinary management as the standard of care.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]